Vaccine Market Valued at $93 Billion by 2026
A recent report by Fortune Business Insights projects the value of the world market for vaccines to reach $93.08 billion by 2026, with a Compound Annual Growth Rate (CAGR) of 10.7 percent during the forecast period.1 One of the main drivers of the vaccine market is the need for greater supplies of vaccines, given stricter government […]
GlaxoSmithKline Partners with Viome to Develop New Vaccines
Vaccine manufacturer GlaxoSmithKline (GSK) of the United Kingdom has partnered with Viome, a gut microbiome test company in Seattle, Washington to better understand bacteria that live in the digestive tract and the role they play in the body’s immune system response.1 According to Emmanuel Hanon, senior vice president for research and development at GSK Vaccines, […]
Medical Errors Kill Five People Per Minute, 2.6 Million People Every Year
A new report published by the World Health Organization (WHO) estimates that 2.6 million people die annually in low-and middle-income countries from medical errors, and that most of those deaths are related to misdiagnosis and administration of pharmaceutical products. According to the WHO, “Four out of every ten patients are harmed during primary and ambulatory […]
CDC Urged to Be Truthful About Its Corporate Financial Ties
Public interest nonprofit organizations U.S. Right to Know and Public Citizen have petitioned the Centers for Disease Control and Prevention (CDC) to stop issuing false disclaimers that it “does not accept commercial support” and has “no financial interests or other relationships with the manufacturers of commercial products.”1 The CDC consistently publishes the following disclaimer throughout […]
Medical “Experts” Were Wrong About the Safety of Opioids
Story Highlights Addiction to and death from prescription painkillers is now a public health crisis in the United States. In the early 1990s, medical “experts” and “thought leaders” made claims convincing the medical community and the public that prescription painkillers were non-addictive when used in the long-term. Financial conflict of interest between opioid manufacturers and […]
Novartis Manipulated Data in FDA Biologics License Application
On Aug. 6, 2019, the U.S. Food and Drug Administration (FDA) issued a statement saying that Swiss pharmaceutical company Novartis AG submitted a biologics license application (BLA) for the spinal muscular atrophy (SMA) gene therapy Zolgensma (onasemnogene abeparvovec-xioi) with manipulated data and failed to inform regulators until June 28, 2019—more than a month after the […]
